Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients.
PURPOSE:Most patients suffering from advanced lung cancer die within a few months. To exploit new therapy regimens we need better methods for the assessment of a therapy response. MATERIAL AND METHODS:In a pilot study we prospectively enrolled 36 patients with advanced NSCLC and SCLC (34 stage IV, 2...
Main Authors: | Bernd Schmidt, Julia Beyer, Dimo Dietrich, Ines Bork, Volker Liebenberg, Michael Fleischhacker |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4326280?pdf=render |
Similar Items
-
Small cell lung cancer(SCLC) disguised as Dysphagia
by: Moka, Nagaishwarya, et al.
Published: (2019) -
Correlation of <it>SHOX2 </it>Gene Amplification and DNA Methylation in Lung Cancer Tumors
by: Liebenberg Volker, et al.
Published: (2011-03-01) -
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
by: Andreas Saltos, et al.
Published: (2020-07-01) -
SCLC-J1, a novel small cell lung cancer cell line
by: Kazuo Ohara, et al.
Published: (2021-09-01) -
Characterization of a new small cell lung cancer (SCLC) cell line STP54 derived from a metastatic bioptate of a combined type of SCLC with Non-SCLC component.
by: Joanna Domagała-Kulawik, et al.
Published: (2009-05-01)